Can-Fite BioPharma Secures US Patent for Obesity Drug Namodenoson
Ticker: CANF · Form: 6-K · Filed: Jan 27, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Jan 27, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, drug-development, obesity
Related Tickers: CFBI
TL;DR
CFBI just got a US patent for Namodenoson as an anti-obesity drug. Big win for IP.
AI Summary
On January 27, 2025, Can-Fite BioPharma Ltd. announced that the US Patent Office granted them a patent for Namodenoson, specifically for its use as an anti-obesity drug. This patent provides Can-Fite with exclusive rights in the United States for this application of Namodenoson.
Why It Matters
This patent grant strengthens Can-Fite's intellectual property portfolio and could pave the way for future commercialization of Namodenoson as a treatment for obesity in the significant US market.
Risk Assessment
Risk Level: medium — While a patent is positive, the actual market success and regulatory approval for Namodenoson as an obesity drug are still uncertain.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Filer of the report and recipient of the patent
- Namodenoson (drug) — The drug for which the patent was granted
- US Patent Office (company) — Granted the patent to Can-Fite
- January 27, 2025 (date) — Date of the press release and patent grant announcement
FAQ
What is the specific indication for which the US patent was granted to Can-Fite BioPharma for Namodenoson?
The US patent was granted for the use of Namodenoson as an anti-obesity drug.
When was the press release announcing the patent grant issued?
The press release was issued on January 27, 2025.
Which entity granted the patent to Can-Fite BioPharma?
The US Patent Office granted the patent.
What is the exact name of the drug mentioned in the filing?
The drug mentioned is Namodenoson.
What form is this SEC filing?
This SEC filing is a Form 6-K, a Report of Foreign Private Issuer.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-01-27 07:03:20
Filing Documents
- ea0228764-6k_canfite.htm (6-K) — 10KB
- ea022876401ex99-1_canfite.htm (EX-99.1) — 16KB
- 0001213900-25-006716.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 27, 2025 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3